Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies

Journal of Neurochemistry

Volumn 79, Issue 3, 2001, Pages 595-605

  Lambert, Mary P ^a   Viola, Kirsten L ^a   Chromy, Brett A ^a   Chang, Lei ^a   Morgan, Todd E ^b   Yu, Jiaxin ^c   Venton, Duane L ^c   Krafft, Grant A ^d   Finch, Caleb E ^b   Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

ADDLs; Alzheimer's disease; Receptors; Therapeutic drugs; Vaccination

Indexed keywords

AMYLOID BETA PROTEIN; NEUTRALIZING ANTIBODY; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); EPITOPE; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; MOUSE; NEUROFILAMENT; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; SOLUBILITY; TRANSGENIC MOUSE; VACCINATION; ANIMAL; ANTIBODY SPECIFICITY; CELL STRAIN; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; HUMAN; IMMUNOLOGY; NERVE CELL; RAT;

ANIMALIA; MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY SPECIFICITY; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; SOLUBILITY; VACCINATION;

EID: 0034740197     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00592.x     Document Type: Article

References (48)

1. Amino acid derivatives of β-cyclodextrin
2. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
3. Isolation and culture of adult rat hippocampal neurons
4. β-Cyclodextrin interacts with the Alzheimer amyloid B-A4 peptide
5. Sequence and methylation in the beta/A4 region of the rabbit amyloid precursor protein gene
6. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging
7. Inflammation in Alzheimer's disease
8. Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease
9. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation
10. Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody
11. Biochemical detection of Abeta isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease
12. Oligomeric Aβ in PBS-soluble extracts of human Alzheimer brain
13. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
14. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
15. Alzheimer's congress. Further progress on a beta-amyloid vaccine
16. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
17. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease
18. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease
19. Quantitation of amyloid β-protein with two monoclonal antibodies
20. Fibrils, protofibrils and Aβ-derived diffusible ligands: How Aβ causes neuron dysfunction and death in Alzheimer's disease
21. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?
22. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains
23. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins
24. Soluble multimeric Alzheimer β (1-40) preamyloid complexes in dilute solution
25. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis
26. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis
27. Reversible inactivation of superoxide-sensitive aconitase in Abetal-42-treated neuronal cell lines
28. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red
29. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease
30. Tau in Alzheimer's disease
31. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
32. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
33. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
34. SDS-stable complex formation between native apolipoprotein E3 and beta-amyloid peptides
35. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress
36. Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state
37. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
38. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
39. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death
40. The Sixth International Conference on Alzheimer's disease, Amsterdam, The Netherlands, July, 1998. The amyloid cascade hypothesis debate: Emerging consensus on the role of A beta and amyloid in Alzheimer's disease
41. Radical AGEing in Alzheimer's disease
42. Disaggregation of Alzheimer beta-amyloid by site-directed mAb
43. Tau protein pathology in neurodegenerative diseases
44. Amyloid beta 1-40 and 1-42: Solubllization parameters and structural outcomes
45. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations
46. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate
47. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates
48. Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimer's Aβ peptide